Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 2 - 45 years of age and at least 10 kg~* Must have clinically severe SCD (SS, SC or SBeta0 Thal) or thalassemia major and be eligible for myeloablative SCT~* Must have two partially HLA-matched CBUs for part 1; and one partially HLA-matched CBU for part 2~* Back-up autologous stem cells harvested from bone marrow~* Adequate Karnofsky Performance score or Lansky Play-Performance scale~* Sufficient physiological reserves~* Signed written informed consent~Exclusion Criteria:~* HLA-matched related donor able to donate~* Severe alloimmunization with inability to guarantee a supply of adequate PRBC donors~* Prior allogeneic hematopoietic SCT within the last 12 months or reduced-intensity transplant within the past 6 months~* Human immunodeficiency virus (HIV) infection~* Active or uncontrolled infection~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- NiCord (Type: EXPERIMENTAL): NiCord: NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).